Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK50042 in Idiopathic Pulmonary Fibrosis
NCT07728721Phase 2Not yet recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Apr 2028
01
Overview
Phase 2, randomised, double-blind trial of HSK50042 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Forced Vital Capacity at 12 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
HSK50042
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07728721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07728721.